| Trial ID: | L0022 |
| Source ID: | NCT06752577
|
| Associated Drug: |
Allogeneic, Vertebral Bone Marrow-Derived Mesenchymal Stem Cells (Msc)
|
| Title: |
Safety and Tolerability of Vertebral Bone Marrow-derived Mesenchymal Stem Cells (BM-MSC) in Real World Scenarios of Patients with Chronic Kidney Disease (CKD)
|
| Acronym: |
|
| Status: |
RECRUITING
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Chronic Kidney Diseases
|
| Interventions: |
DRUG: Allogeneic, vertebral bone marrow-derived mesenchymal stem cells (MSC)
|
| Outcome Measures: |
Primary: Adverse events and/or serious adverse events, Number of adverse events and/or serious adverse events associated with mesenchymal stem cells intervention, 6 months |
|
| Sponsor/Collaborators: |
Sponsor: Mayo Clinic | Collaborators: Ossium Health, Inc.
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
|
| Enrollment: |
50
|
| Study Type: |
OBSERVATIONAL
|
| Study Designs: |
Observational Model: |Time Perspective: p
|
| Start Date: |
2024-12-22
|
| Completion Date: |
2031-12-31
|
| Results First Posted: |
|
| Last Update Posted: |
2024-12-30
|
| Locations: |
Mayo Clinic, Jacksonville, Florida, 32224, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT06752577
|
